Healius Completes Sale of Lumus Imaging, Refocuses on Pathology

Healius Limited ( (AU:HLS) ) has issued an announcement.

Healius Limited has completed the sale of Lumus Imaging to Affinity Equity Partners for $822 million, allowing Healius to focus on its pathology strategy and streamline operations. The transaction will enable Healius to pay a special dividend and provide transitional services to Lumus Imaging for up to eighteen months, ensuring a smooth transition for both the company and its patients.

More about Healius Limited

For over 30 years, Healius Limited has been a leading healthcare company in Australia, dedicated to providing quality, affordable, and accessible healthcare services. With a network of centers and over 8,500 employees, Healius specializes in offering specialty pathology services across the country to consumers and their referring practitioners.

YTD Price Performance: -7.93%

Average Trading Volume: 1,194

Technical Sentiment Signal: Strong Buy

Current Market Cap: €573.6M

For a thorough assessment of HLS stock, go to TipRanks’ Stock Analysis page.